Survival in patients with multiple myeloma: evaluation of possible associations with bone marrow fibrosis and investigation of factors independently associated with survival

Bulletin of the National Research Centre

Table 4 Comparison of Progression-free survival times (months) after the first treatment calculated using Kaplan–Meier analysis and groups with Log-rank test

	n	Progression	Mean ± Standard Error (95% CI)	p
Progression-free survival	59	53	14.07 ± 2.54 (9.09–19.05)	N/A
Age
< 60	25	23	7.34 ± 2.13 (3.17–11.52)	0.011
≥ 60	34	30	18.52 ± 3.75 (11.16–25.87)
Sex
Male	34	30	16.03 ± 3.66 (8.86–23.21)	0.364
Female	25	23	11.51 ± 3.27 (5.09–17.92)
Comorbidity
No	21	20	10.91 ± 3.48 (4.08–17.73)	0.203
Yes	38	33	15.78 ± 3.46 (9.00–22.55)
Type
Heavy chain	47	44	9.89 ± 1.99 (6.00–13.78)	0.007
Light chain	12	9	30.22 ± 8.44 (13.68–46.77)
Stage
Others	16	14	21.98 ± 5.18 (11.82–32.14)	0.024
Stage III (A/B)	38	37	8.82 ± 2.55 (3.82–13.82)
Lytic lesion
No	15	15	5.67 ± 1.52 (2.69–8.64)	0.692
Yes	26	26	6.65 ± 2.78 (1.20–12.10)
Plasmacytoma
No	36	32	11.11 ± 2.67 (5.88–16.35)	0.247
Yes	21	20	17.55 ± 4.73 (8.27–26.83)
Hypercalcemia
No	47	42	13.11 ± 2.78 (7.66–18.57)	0.396
Yes	8	7	21.63 ± 9.23 (3.53–39.72)
High creatinine (> 2)
No	46	42	13.75 ± 2.68 (8.50–19.01)	0.971
Yes	13	11	13.69 ± 5.81 (2.31–25.08)
Bone marrow fibrosis level
0	14	12	20.55 ± 6.59 (7.64–33.47)	0.220
1–4	44	40	12.61 ± 2.73 (7.26–17.95)

p values marked with bold indicate statistically significant differences between the groups